274 related articles for article (PubMed ID: 37096751)
1. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
[TBL] [Abstract][Full Text] [Related]
2. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
[TBL] [Abstract][Full Text] [Related]
3. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V
ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384
[TBL] [Abstract][Full Text] [Related]
4. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
5. Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer.
Turchiano A; Piglionica M; Martino S; Bagnulo R; Garganese A; De Luisi A; Chirulli S; Iacoviello M; Stasi M; Tabaku O; Meneleo E; Capurso M; Crocetta S; Lattarulo S; Krylovska Y; Lastella P; Forleo C; Stella A; Bukvic N; Simone C; Resta N
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628581
[TBL] [Abstract][Full Text] [Related]
6. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
7. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity.
Bu R; Siraj AK; Al-Rasheed M; Iqbal K; Azam S; Qadri Z; Haqawi W; Tulbah A; Al-Dayel F; Almalik O; Al-Kuraya KS
Sci Rep; 2023 Nov; 13(1):20924. PubMed ID: 38017116
[TBL] [Abstract][Full Text] [Related]
9. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
11. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Yadav S; Hu C; Hart SN; Boddicker N; Polley EC; Na J; Gnanaolivu R; Lee KY; Lindstrom T; Armasu S; Fitz-Gibbon P; Ghosh K; Stan DL; Pruthi S; Neal L; Sandhu N; Rhodes DJ; Klassen C; Peethambaram PP; Haddad TC; Olson JE; Hoskin TL; Goetz MP; Domchek SM; Boughey JC; Ruddy KJ; Couch FJ
J Clin Oncol; 2020 May; 38(13):1409-1418. PubMed ID: 32125938
[TBL] [Abstract][Full Text] [Related]
13. Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
Ow SGW; Ong PY; Lee SC
PLoS One; 2019; 14(3):e0213746. PubMed ID: 30875412
[TBL] [Abstract][Full Text] [Related]
14. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
Front Oncol; 2022; 12():976959. PubMed ID: 36119527
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
17. Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.
Acevedo F; Walbaum B; Camus M; Manzor M; Muñiz S; Medina L; Petric M; Reyes P; Domínguez F; Puschel K; Merino T; Bravo ML; Pinto MP; Ibáñez C; Hughes K; Sánchez C
Breast Cancer Res Treat; 2023 Jun; 199(2):363-370. PubMed ID: 36988750
[TBL] [Abstract][Full Text] [Related]
18. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
[TBL] [Abstract][Full Text] [Related]
19. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
[TBL] [Abstract][Full Text] [Related]
20. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]